| pubmed-article:3036936 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3036936 | lifeskim:mentions | umls-concept:C0019169 | lld:lifeskim |
| pubmed-article:3036936 | lifeskim:mentions | umls-concept:C0037140 | lld:lifeskim |
| pubmed-article:3036936 | lifeskim:mentions | umls-concept:C0152035 | lld:lifeskim |
| pubmed-article:3036936 | lifeskim:mentions | umls-concept:C0524909 | lld:lifeskim |
| pubmed-article:3036936 | lifeskim:mentions | umls-concept:C0279030 | lld:lifeskim |
| pubmed-article:3036936 | pubmed:dateCreated | 1987-8-5 | lld:pubmed |
| pubmed-article:3036936 | pubmed:abstractText | Hepatitis B virus (HBV) infection is prevalent in Chinese populations. 40.4% of 383 Chinese HBV carriers studied were HBeAg-positive. The annual rate of spontaneous clearance of HBeAg was 11%. Twenty-six patients with HBsAg- and HBeAg- and HBeAg-positive non-malignant chronic liver disease randomised to receive recombinant alpha-2 interferon or no treatment have been followed for 6 months or longer. Seven of the 20 treated patients cleared HBeAg during or shortly after treatment but this was sustained in only 1 patient. One of the 6 controls had transient loss of HBeAg. It is too early to conclude whether interferon has any long-term effect on the suppression of HBV replication in Chinese patients. Sixty-nine patients with histologically proven hepatocellular carcinoma were randomised to receive adriamycin or interferon. Although there was no significant benefit on survival, interferon therapy was associated with greater than 25% regression in tumor size in 12.5% of patients and less toxicity. | lld:pubmed |
| pubmed-article:3036936 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3036936 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3036936 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3036936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3036936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3036936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3036936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3036936 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3036936 | pubmed:issn | 0168-8278 | lld:pubmed |
| pubmed-article:3036936 | pubmed:author | pubmed-author:LowA GAG | lld:pubmed |
| pubmed-article:3036936 | pubmed:author | pubmed-author:LaiC LCL | lld:pubmed |
| pubmed-article:3036936 | pubmed:author | pubmed-author:WuP CPC | lld:pubmed |
| pubmed-article:3036936 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3036936 | pubmed:volume | 3 Suppl 2 | lld:pubmed |
| pubmed-article:3036936 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3036936 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3036936 | pubmed:pagination | S209-15 | lld:pubmed |
| pubmed-article:3036936 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:meshHeading | pubmed-meshheading:3036936-... | lld:pubmed |
| pubmed-article:3036936 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3036936 | pubmed:articleTitle | Interferon therapy of chronic hepatitis B virus infection in Chinese. | lld:pubmed |
| pubmed-article:3036936 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3036936 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3036936 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:3036936 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3036936 | lld:pubmed |
